Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $563.2 million.

  • CureVac's Cash & Equivalents rose 2742.41% to $563.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $563.2 million, marking a year-over-year increase of 2742.41%. This contributed to the annual value of $514.8 million for FY2024, which is 1888.61% up from last year.
  • Per CureVac's latest filing, its Cash & Equivalents stood at $563.2 million for Q3 2025, which was up 2742.41% from $444.5 million recorded in Q2 2025.
  • In the past 5 years, CureVac's Cash & Equivalents registered a high of $1.6 billion during Q1 2021, and its lowest value of $910736.6 during Q1 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $506.7 million (2025), whereas its average is $531.8 million.
  • As far as peak fluctuations go, CureVac's Cash & Equivalents plummeted by 9994.29% in 2022, and later surged by 5833178.51% in 2023.
  • Over the past 5 years, CureVac's Cash & Equivalents (Quarter) stood at $928.3 million in 2021, then tumbled by 45.51% to $505.8 million in 2022, then fell by 14.4% to $433.0 million in 2023, then grew by 18.89% to $514.8 million in 2024, then increased by 9.4% to $563.2 million in 2025.
  • Its last three reported values are $563.2 million in Q3 2025, $444.5 million for Q2 2025, and $506.7 million during Q1 2025.